Neurodoc's Blog : Buy BIIB

Biogen has Avonex (still very useful as first line therapy for MS), Tysabri, extremely useful despite the PML risk, and this new oral drug very likely to be approved later next year, and could be the preferred first-line treatment (see below).  BIIB is now a fixture in my porfolio.

Related Quotes Sym. Price Chg. BIIB Trade News 99.6 0.95 MARKET TALK: Biogen's MS Drug Has 'Blue Sky Potential' Jun 22, 2011 13:50:20 (ET) 1:50 (Dow Jones) There's "blue sky potential" for Biogen's (BIIB) pill BG12 to become the "corner stone" multiple-sclerosis therapeutic, notes Credit Suisse after upgrading the company's rating to buy. The firm is optimistic about BG12's commercial prospects and says it's a factor that could lead to BIIB having the "most robust long term revenue and earning profile" among large-cap biotech companies. BG12's success "will likely significantly drive down" BIIB's R&D cost base as a percentage of revenues, Credit Suisse says. BIIB climbs 1.7% to $100.49. The stock has soared 102% in the last year. (siddhartha.v@dowjones.com) Call us at (212) 416-2184 or email siddhartha.vaidyanathan@dowjones.com (END) Dow Jones Newswires June 22, 2011 13:50 ET (17:50 GMT)